Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
476 stopped studies mapped to Malignant Ovarian Neoplasm and descendants · 86% state a reason
Over the 476 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00653328 | Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary… | Phase 2 | terminated | Apr 4, 2008 | Vanderbilt-Ingram Cancer Center | Abbott (drug manufacturer) discontinued manufacture of ABT-627 | Drug supply |
| NCT00813254 | Cost Utility Analysis in Recurrent Ovarian Cancer | — | withdrawn | Dec 23, 2008 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00505661 | Letrozole in Patients With Ovarian Tumors | Phase 2 | terminated | Jul 23, 2007 | M.D. Anderson Cancer Center | Terminated due to slow patient accrual. | Enrollment / accrual |
| NCT00253461 | 11C Topotecan PET Imaging | Early Phase 1 | terminated | Nov 15, 2005 | Case Comprehensive Cancer Center | Drugs unavailable:unable to make radioactive topotecan | Other (stated, no rule matched) |
| NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating… | Phase 1 | terminated | Oct 1, 2010 | Cancer Research UK | due to safety concerns and lack of efficacy | Safety / toxicity |
| NCT01096381 | Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid… | — | terminated | Mar 31, 2010 | Vanderbilt-Ingram Cancer Center | funding withdrawn due to fellow's departure from VICC | Funding |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian…(MIMOSA) | Phase 2 / Phase 3 | terminated | Jan 5, 2007 | Menarini Group | No benefit on primary end point (RFS); no rationale to collect survival data | Other (stated, no rule matched) |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125… | Phase 2 | terminated | Jun 23, 2009 | Hellenic Cooperative Oncology Group | The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the… | Enrollment / accrual |
| NCT00898781 | Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or… | — | terminated | May 12, 2009 | Mayo Clinic | Due to poor accrual | Enrollment / accrual |
| NCT00118300 | Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical… | Phase 1 | withdrawn | Jul 11, 2005 | Case Comprehensive Cancer Center | Competing studies | Other (stated, no rule matched) |
| NCT00531778 | NYU Ovarian Cancer Early Detection Program Blood and Genetics | — | terminated | Sep 19, 2007 | NYU Langone Health | insufficient funding and resource | Funding |
| NCT00082212 | A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal… | Phase 2 | terminated | May 5, 2004 | Eli Lilly and Company | Due to lack of sufficient efficacy. | Efficacy / futility |
| NCT00277290 | Study of XL999 in Patients With Previously Treated Ovarian Cancer | Phase 2 | terminated | Jan 16, 2006 | Symphony Evolution, Inc. | Study was terminated due to cardiac toxicities in the subjects | Safety / toxicity |
| NCT01000896 | Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and… | Phase 1 | withdrawn | Oct 23, 2009 | AstraZeneca | AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical… | Other (stated, no rule matched) |
| NCT00317434 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian… | Phase 1 | terminated | Apr 24, 2006 | University of Alabama at Birmingham | Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited clinical… | Safety / toxicity |
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing… | Phase 2 | withdrawn | Feb 8, 2008 | Millennium Pharmaceuticals, Inc. | Study never submitted to IND. Study is being sponsored by Johnson and Johnson in the EU only. | Other (stated, no rule matched) |
| NCT00753480 | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial… | Phase 1 | suspended | Sep 16, 2008 | Genentech, Inc. | not stated | Not stated |
| NCT00050375 | Clinical Trial for Ovarian Cancer (OvaRex®) | Phase 3 | terminated | Dec 6, 2002 | Unither Pharmaceuticals | Study closed by sponser | Other (stated, no rule matched) |
| NCT00086632 | Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer… | Phase 2 | terminated | Jul 9, 2004 | Unither Pharmaceuticals | closed by sponser | Other (stated, no rule matched) |
| NCT00047632 | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal… | Phase 3 | terminated | Oct 11, 2002 | InterMune | futility | Efficacy / futility |
| NCT00189579 | Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer | Phase 2 | terminated | Sep 19, 2005 | ARCAGY/ GINECO GROUP | not stated | Not stated |
| NCT00287482 | Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With… | N/A | terminated | Feb 6, 2006 | Women and Infants Hospital of Rhode Island | not stated | Not stated |
| NCT00055432 | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent… | Phase 2 | terminated | Mar 4, 2003 | Eli Lilly and Company | not stated | Not stated |
| NCT00194935 | Weekly Topotecan Therapy in Patients With Ovarian Cancer | Phase 2 | terminated | Sep 19, 2005 | Weill Medical College of Cornell University | not stated | Not stated |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And… | Phase 1 / Phase 2 | terminated | Sep 16, 2005 | Celgene Corporation | not stated | Not stated |
| NCT00189371 | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin… | Phase 3 | terminated | Sep 19, 2005 | AGO Study Group | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 23, 2012source: clinicaltrials